WallStSmart
CAH

Cardinal Health Inc

NYSE: CAH · HEALTHCARE · MEDICAL DISTRIBUTION

$192.88
-4.90% today

Updated 2026-04-30

Market cap
$47.73B
P/E ratio
29.14
P/S ratio
0.20x
EPS (TTM)
$6.96
Dividend yield
0.99%
52W range
$137 – $233
Volume
1.7M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Cardinal Health Inc (CAH) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$192.88
Consensus
$230.45
+19.48%
2030 Target
$18,344.09
+9410.62%
DCF
$834.93
+73.14% MoS
11 analysts:
7 Buy1 Hold0 Sell

Management guidance

Management has not provided explicit revenue targets through 2030 in available guidance. However, Cardinal Health raised FY2026 guidance significantly, with analyst consensus now projecting $261.25B revenue for FY2026 (ending June 30, 2026), representing 17.4% growth. The company's specialty drug distribution and radiopharmaceutical expansion (Ac-225 capacity increases announced April 2026) are expected to drive sustained mid-to-high single-digit growth through 2030.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$30,566.34
$359.7B Rev × 20x P/S
Base case (2030)
$18,344.09
$359.7B Rev × 12x P/S
Bear case (2030)
$12,222.26
$359.7B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$205.0B$226.8B$222.6B$261.3B$284.8B$309.6B$334.3B$359.7B
Revenue growth—10.7%-1.9%17.4%9.0%8.7%8.0%7.6%
EPS—$7.47$5.18$10.41$11.69$13.15$14.62$16.18
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$13,313.91$14,512.59$15,796.89$17,038.38$18,344.09

Catalysts & risks

Growth catalysts
+ Actinium-225 radiopharmaceutical capacity expansion supporting novel cancer therapy trials and future commercial manufacturing (announced April 2026)
+ Specialty drug distribution flywheel strategy integrating MSO platforms and biopharma services to capture higher-margin oncology and specialty pharmaceutical segments
+ Biosimilar adoption momentum and cost savings driver for healthcare providers, expanding Cardinal's specialty distribution role
+ Potential pharmaceutical pricing regulation changes that could redirect patient demand toward generic and specialty distribution channels
Key risks
- Drug pricing policy regulation could compress pharmaceutical distribution margins and limit revenue growth in core business
- Integration and execution risk on specialty flywheel strategy and radiopharmaceutical expansion requiring significant capex
- Competitive pressure from McKesson and Cencora on market share in high-margin specialty and pharmaceutical distribution segments
- Healthcare system consolidation and direct-to-manufacturer purchasing could bypass traditional distribution channels

Methodology

Cardinal Health Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 11 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.